🔎 Trials Near Me

Home › Sickle Cell Disease › Alabama › Birmingham

Pag-aaral pangklinika para sa Sickle Cell Disease sa Birmingham, AL

14 pag-aaral para sa Sickle Cell Disease ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Birmingham (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

Nagre-recruitPhase 1
  • University of Alabama at Birmingham, Birmingham
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07187973

A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

Nagre-recruitPhase 3
  • Uni of Alabama at Birmingham, Birmingham
Edad 12 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06612268

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
  • University of Alabama Birmingham, Birmingham
Edad 12 hanggang 55 · Lahat ng kasarian · Na-update Set 9, 2026 · NCT06546670

SCD Stem Cell Mobilization and Apheresis Using Motixafortide

Nagre-recruitPhase 1
  • University of Alabama at Birmingham, Birmingham
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06442761

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
  • University of Alabama at Birmingham, Birmingham
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT06481306

The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease

Nagre-recruitPhase 3
  • University of Alabama at Birmingham- Site Number : 8400003, Birmingham
Edad 10 hanggang 65 · Lahat ng kasarian · Na-update Hul 29, 2026 · NCT06975865

Early Life Exposures Among Children With Sickle Cell Disease

Nagre-recruit
  • University of Alabama at Birmingham, Birmingham
Edad 18 hanggang 50 · Kababaihan · Na-update Hul 15, 2026 · NCT05377372

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Nagre-recruitPhase 4
  • University Of Alabama, Birmingham
6 Months – 100 Years · Lahat ng kasarian · Na-update Hun 8, 2026 · NCT04657822

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

Nagre-recruitObservasyonal na pag-aaral
  • Children's of Alabama (MRD-HCT), Birmingham
  • Children's of Alabama (NT-DMT), Birmingham
Edad 3 hanggang 20 · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT06941389

Cognitive Remediation Intervention to Prepare for Transition of Care

Nagre-recruitPhase 2
  • University of Alabama at Birmingham, Birmingham
Edad 10 hanggang 18 · Lahat ng kasarian · Na-update Peb 27, 2026 · NCT05336201

A Long-term Follow-up Study in Patients Who Received BEAM-101

Nagre-recruitObservasyonal na pag-aaral
  • University of Alabama at Birmingham, Birmingham
Edad 14 hanggang 37 · Lahat ng kasarian · Na-update Ene 28, 2026 · NCT07373639

HPC Offered for PRESERVE Expansion

Nagre-recruitObservasyonal na pag-aaral
  • University of Alabama, Birmingham, Birmingham
Edad 12 hanggang 80 · Lahat ng kasarian · Na-update Ago 28, 2025 · NCT07145411

Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease

Nagre-recruitObservasyonal na pag-aaral
  • University of Alabama, Birmingham (UAB), Birmingham
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 22, 2025 · NCT06385886

Pag-aaral para sa Sickle Cell Disease sa ibang lungsod

Iba pang pag-aaral sa Birmingham

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.